Endocannabinoids and β-amyloid-induced neurotoxicity in vivo: Effect of pharmacological elevation of endocannabinoid levels

Cellular and Molecular Life Sciences

Volumn 63, Issue 12, 2006, Pages 1410-1424

  Van Der Stelt, M ^a,e   Mazzola, C ^b   Esposito, G ^c   Matias, I ^a   Petrosino, S ^a   De Filippis, D ^c   Micale, V ^b   Steardo, L ^d   Drago, F ^b   Iuvone, T ^c   Di Marzo, V ^a  

^a CNR   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e NV ORGANON   (Netherlands)

Author keywords

2 arachidonoyl glycerol; Anandamide; Apoptosis; Cannabinoid; Memory; Neuroprotection; Receptor

Indexed keywords

2 ARACHIDONOYLGLYCEROL; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMYLOID BETA PROTEIN[1-42]; ANANDAMIDE; ENDOCANNABINOID; ENDOCANNABINOID REUPTAKE INHIBITOR; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN DAMAGE; BRAIN LEVEL; CONTROLLED STUDY; HIPPOCAMPUS; MALE; MEMORY CONSOLIDATION; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE AVOIDANCE; RAT;

AMYLOID BETA-PROTEIN; ANIMALS; ARACHIDONIC ACIDS; AVOIDANCE LEARNING; ENDOCANNABINOIDS; GLYCERIDES; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; MEMORY; MICE; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; PEPTIDE FRAGMENTS; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; RNA, MESSENGER; STEREOTAXIC TECHNIQUES; TIME FACTORS;

RODENTIA;

EID: 33745327044     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-006-6037-3     Document Type: Article

References (65)

1. Di Marzo, V., Bifulco, M. and De Petrocellis, L. (2004) The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3, 771-784.
2. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A. and Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
3. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., Pertwee, R. G., Griffin, G., Bayewitch, M., Barger, J. and Vogel, Z. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90.
4. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A. and Waku, K. (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97.
5. Hampson, R. E. and Deadwyler, S. A. (1999) Cannabinoids, hippocampal function and memory. Life Sci. 65, 715-723.
6. Shen, M. and Thayer, S. A. (1999) Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol. Pharmacol. 55, 8-13.
7. Nagayama, T., Sinor, A. D., Simon, R. P., Chen, J., Graham, S. H., Jin, K. and Greenberg, D. E. (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19, 2987-2995.
8. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R. and Shohami, E. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527-531.
9. van der Stelt, M., Veldhuis, W. B., van Haaften, G. W., Fezza, F., Bisogno, T., Bar, P. R., Veldink, G. A., Vliegenthart, J. F., Di Marzo, V. and Nicolay, K. (2001) Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21, 8765-8771.
10. Hansen, H. H., Schmid, P. C., Bittigau, P., Lastres-Becker, I., Berrendero, F., Manzanares, J., Ikonomidou, C., Schmid, H. H., Fernandez-Ruiz, J. J. and Hansen, H. S. (2001) Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 78, 1415-1427.
11. Veldhuis, W. B., van der Stelt, M., Wadman, M. W., van Zadelhoff, G., Maccarrone, M., Fezza, F., Veldink, G. A., Vliegenthart, J. F., Bar, P. R., Nicolay, K. and Di Marzo, V. (2003) Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J. Neurosci. 23, 4127-4133.
12. Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutierrez, S. O., van der Stelt, M., Lopez-Rodriguez, M. L., Casanova, E., Schutz, G., Zieglgansberger, W., Di Marzo, V., Behl, C. and Lutz, B. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88.
13. Wallace, M. J., Blair, R. E., Falenski, K. W., Martin, B. R. and DeLorenzo, R. J. (2003) The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 307, 129-137.
14. Guzman, M. (2003) Neurons on cannabinoids: dead or alive? Br. J. Pharmacol. 140, 439-140.
15. Walter, L. and Stella, N. (2004) Cannabinoids and neuroinflammation. Br. J. Pharmacol. 141, 775-785.
16. van der Stelt, M., Hansen, H. H., Veldhuis, W. B., Bar PR., Nicolay, K., Veldink, G. A., Vliegenthart, J. F. and Hansen, H. S. (2003) Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases. Neurotox. Res. 5, 183-200.
17. Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sorgard, M., Di Marzo, V., Julius, D. and Hogestatt, E. D. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457.
18. Pegorini, S., Braida, D., Verzoni, C., Guerini-Rocco, C., Consalez, G. G., Croci, L. and Sala, M. (2005) Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. Br. J. Pharmacol. 144, 727-735.
19. Fernandez-Ruiz, J., Lastres-Becker, I., Cabranes, A., Gonzalez, S. and Ramos, J. A. (2002) Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot. Essent. Fatty Acids 66, 257-267.
20. Baker, D. and Pryce, G. (2003) The therapeutic potential of cannabis in multiple sclerosis. Expert Opin. Invest. Drugs 12, 561-567.
21. Benito, C., Nunez, E., Tolon, R. M., Carrier, E. J., Rabano, A., Hillard, C. J. and Romero, J. (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23, 11136-11141.
22. Milton, N. G. (2002) Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci. Lett. 332, 127-130.
23. Ramirez, B. G., Blazquez, C., Gomez del Pulgar, T., Guzman, M. and de Ceballos, M. L. (2005) Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25, 1904-1913.
24. Lichtman, A. H., Varvel, S. A. and Martin, B. R. (2002) Endocannabinoids in cognition and dependence. Prostaglandins Leukot. Essent. Fatty Acids 66, 269-285.
25. Davies, S. N., Pertwee, R. G. and Riedel, G. (2002) Functions of cannabinoid receptors in the hippocampus. Neuropharmacology 42, 993-1007.
26. Castellano, C., Cabib, S., Palmisano, A., Di Marzo, V. and Puglisi-Allegra, S. (1997) The effects of anandamide on memory consolidation in mice involve both D1 and D2 dopamine receptors. Behav. Pharmacol. 8, 707-712.
27. Hernandez-Tristan, R., Arevalo, C., Canals, S. and Leret, M. L. (2000) The effects of acute treatment with delta9-THC on exploratory behaviour and memory in the rat. J. Physiol. Biochem. 56, 17-24.
28. Castellano, C., Rossi-Arnaud, C., Cestari, V. and Costanzi, M. (2003) Cannabinoids and memory: animal studies. Curr. Drug Targets CNS Neurol. Disord. 2, 389-402.
29. Lichtman, A. H. (2000) SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur. J. Pharmacol. 404, 175-179.
30. Wolff, M. C. and Leander, J. D. (2003) SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task. Eur. J. Pharmacol. 477, 213-217.
31. Hampson, R. E., Simeral, J. D., Kelly, E. J. and Deadwyler, S. A. (2003) Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons. Hippocampus 13, 543-556.
32. Mazzola, C., Micale, V. and Drago, F. (2003) Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur. J. Pharmacol. 477, 219-225.
33. Flood, J. F., Morley, J. E. and Roberts, E. (1991) Amnestic effects in mice of four synthetic peptides homologous to amyloid beta protein from patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA 88, 3363-3366.
34. Emre, M., Geula, C., Ransil, B. J. and Mesulam, M. M. (1992) The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected beta-amyloid in the rat brain. Neurobiol. Aging 13, 553-559.
35. Harkany, T., Hortobagyi, T., Sasvari, M., Konya, C., Penke, B., Luiten, P. G. and Nyakas, C. (1999) Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 23, 963-1008.
36. Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R. and Di Marzo, V. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845-852.
37. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M. and Izzo, A. A. (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa on β-amyloid-induced toxicity in PC12 cells. J. Neurochem. 89. 134-141.
38. Esposito, G., De Filippis, D., Carnuccio, R., Izzo, A. A. and Iuvone, T. (2005) The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J. Mol. Med. 84, 253-258.
39. Kowall, N. W., Beal, M. F., Busciglio, J., Duffy, L. K. and Yankner, B. A. (1991) An in vivo model for neurodegenerative effects of β-amyloid and protection by substance, P. Proc. Natl. Acad. Sci. USA 88,7247-7251.
40. De Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G. and Di Marzo, V. (2000) Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 483, 52-56.
41. Chan, P. H., Kawase, M., Murakami, K., Chen, S. F., Li, Y., Calagui, B., Reola, L., Carlson, E. and Epstein, C. J. (1998) Overexpression of SOD1 in transgenic rats protects vulnerable neurons against ischemic damage after global cerebral ischemia and reperfusion. J. Neurosci. 18, 8292-9299.
42. Maurice, T., Lockhart, B. P. and Privat, A. (1996) Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res. 706, 181-193.
43. Bisogno, T., Melck, D., De Petrocellis, L., Bobrov, M. Yu., Gretskaya, N. M., Bezuglov, V. V. Sitachitta, N., Gerwick, W. H. and Di Marzo, V. (1998) Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 248, 515-522.
44. Venault, P., Chapouthier, G., de Carvalho, L. P., Simiand, J., Morre, M., Dodd, R. H. and Rossier, J. (1986) Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature 321, 864-866.
45. de Lago, E., Ligresti, A., Ortar, G., Morera, E., Cabranes, A., Pryce, G., Bifulco, M., Baker, D., Fernandez-Ruiz, J. and Di Marzo, V. (2004) In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur. J. Pharmacol. 484, 249-257.
46. Heffner, T. G., Hartman, J. A. and Seiden, L. S. (1980) A rapid method for the regional dissection of the rat brain. Pharmacol. Biochem. Behav. 13, 453-456.
47. Schmid, P. C., Krebsbach, R. J., Perry, S. R., Dettmer, T. M., Maasson, J. L. and Schmid, H. H. (1995) Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 375, 117-120.
48. Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Batkai, S., Jarai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T. and Kunos, G. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822-825.
49. Scali, C., Prosperi, C., Giovannelli, L., Bianchi, L., Pepeu, G. and Casamenti, F. (1999) Beta(1-40) amyloid peptide injection into the nucleus basalis of rats induces microglia reaction and enhances cortical gamma-aminobutyric acid release in vivo. Brain Res. 831, 319-321.
50. Richardson, R. L., Kim, E. M., Shephard, R. A., Gardiner, T., Cleary, J. and O'Hare, E. (2002) Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. Brain Res. 954, 1-10.
51. de Lago, E., Fernandez-Ruiz, J., Ortega-Gutierrez, S., Cabranes, A., Pryce, G., Baker, D., Lopez-Rodriguez, M. and Ramos, J. A.(2006) UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur. Neuropsychopharmacol. 16, 7-18.
52. Ramirez, G., Toro, R., Dobeli, H. and von Bernhardi, R. (2005) Protection of rat primary hippocampal cultures from A beta cytotoxicity by pro-inflammatory molecules is mediated by astrocytes. Neurobiol. Dis. 19, 243-254.
53. Kadowaki, H., Nishitoh, H., Urano, F., Sadamitsu, C., Matsuzawa, A., Takeda, K., Masutani, H., Yodoi, J., Urano, Y., Nagano, T. and Ichijo, H. (2005) Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ. 12, 19-24.
54. Patel, S., Roelke, C. T., Rademacher, D. J., Cullinan, W. E. and Hillard, C. J. (2004) Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145, 5431-5438.
55. Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E. J., Gangadharan, U., Hobbs, C., Di Marzo, V. and Doherty, P. (2003) Cloning of the first snl-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell. Biol. 163, 463-468.
56. Farooqui, A. A., Liss, L. and Horrocks, L. A. (1988) Neurochemical aspects of Alzheimer's disease: involvement of membrane phospholipids. Metab. Brain Dis. 3, 19-35.
57. Al-Hayani, A., Wease, K. N., Ross, R. A., Pertwee, R. G. and Davies, S. N. (2001) The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. Neuropharmacology 41, 1000-1005.
58. Shen, M. and Thayer, S. A. (1999) Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54, 459-462.
59. Zhuang, S. Y., Bridges, D., Grigorenko, E., McCloud, S., Boon, A., Hampson, R. E. and Deadwyler, S. A. (2005) Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology 48, 1086-1096.
60. + current in hippocampal CA1 pyramidal neurons. Biochem. Biophys. Res. Commun. 338, 1913-1919.
61. Maccarrone, M., Gubellini, P., Bari, M., Picconi, B., Battista, N., Centonze, D., Bernardi, G., Finazzi-Agrò, A. and Calabresi, P. (2003) Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem. 85, 1018-1025.
62. Di Marzo, V., Hill, M. P., Bisogno, T., Crossman, A. R. and Brotchie, J. M. (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14, 1432-1438.
63. Fernandez-Espejo, E., Caraballo, I., de Fonseca, F. R., El Banoua, F., Ferrer, B., Flores, J. A. and Galan-Rodriguez, B. (2005) Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol. Dis. 18, 591-601.
64. van der Stelt, M., Fox, S. H., Hill, M., Crossman, A. R., Petrosino, S., Di Marzo, V. and Brotchie, J. (2005) A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J. 19, 1140-1142.
65. Di Marzo, V. and De Petrocellis, L. (2006) Non-CB1, non-CB2 receptors for endocannabinodis. In: Endocannabinoids (Onaivi E., Sugiura T. and Di Marzo V., Eds.), pp. 151-174. CRC-Press/Taylor & Francis, Boca Raton.